| |
Our objective is to become a leading
biotechnology company by applying our understanding of complex sugars
and our proprietary technology to drug discovery, development, and commercialization.
The key elements of our strategy are to:
| • |
Maximize the commercial potential of our near-term
product opportunities |
| • |
Advance our improved development product opportunities
into clinical trials |
| • |
Leverage our proprietary technology and apply
our understanding of sugars to create novel therapeutics to address
critical unmet needs |
| • |
Enhance our internal development programs through
selective partnering |
| • |
Establish development capabilities and sales
and marketing capabilities focused on key in-hospital markets |
We believe our business strategy provides for both
long-term value creation and near-term revenue opportunities.
| • |
Momenta’s goal is to pursue a variety
of near-term development opportunities which apply our technology
to create either generic or improved versions of existing products
and molecules. |
| • |
We will build long-term value by applying our
understanding of the role sugars play in basic biology and in disease
onset, progression, and treatment to develop novel drugs, addressing
unmet needs in areas such as cancer, cardiovascular disease, Alzheimer’s
disease, inflammatory disease, and viral infection. |
• We believe Momenta’s ultimate success
will be defined by its ability to effectively prioritize and select
among multiple strategic opportunities to bring drugs to market. To
this end, Momenta has assembled a leadership team comprised of experienced
biotechnology and pharmaceutical industry executives and recognized
experts in glycobiology. We believe this team provides us with significant
capabilities in the discovery, development, and commercialization of
therapeutics, including an ability to apply a cross-disciplinary approach
to guide the Company’s growth and development. |
|
| Momenta's business strategy provides for
both long-term value and accelerated product opportunities with
reduced risk. |
|
